Seattle Genetics Inc (SGEN) 40.38 $SGEN
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 40.38 (-0.63)
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 40.38 (-0.63)
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 40.38 (-0.63)
Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 40.38 (-0.63)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SGEN: 40.38 (-0.63), SNY: 39.41 (-1.45)
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 40.38 (-0.63)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.38 (-0.63), OPHT: 56.33 (+0.17), THLD: 0.47 (-0.02), CHMA: 2.91 (-0.23)
Taking Inventory on Seattle Genetics, Inc. Earnings
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 5:04PM CDT
Seattle Genetics released first-quarter earnings results on Thursday, and while sales of Adcetris continued to grow, they weren't quite as robust as investors were hoping for. Seattle Genetics results: The raw numbers ...
SGEN: 40.38 (-0.63)
Seattle Genetics to Present at Upcoming Investor Conferences
BusinessWire - Wed May 04, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section.
SGEN: 40.38 (-0.63)
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 42.30 (-1.19), SGEN: 40.38 (-0.63), AEGR: 1.37 (-0.13)
Seattle Genetics reports 1Q loss
Automated Insights - Thu Apr 28, 4:59PM CDT
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a loss of $20.5 million in its first quarter.
SGEN: 40.38 (-0.63)
Seattle Genetics Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:02PM CDT
---Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016-
SGEN: 40.38 (-0.63)
5 Biotech Stocks to Bet on This Earnings Season
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 1:42PM CDT
The happening biotech sector should be a good bet for investors.
BMRN: 81.10 (-1.84), SGEN: 40.38 (-0.63), GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25)
Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
BusinessWire - Mon Apr 18, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company's antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. The presentations describe preclinical data with SGN-LIV1A and SEA-CD40, which are in ongoing clinical trials, and highlight two preclinical programs, a novel ADC for the treatment of multiple myeloma (SGN-CD352A) and a small molecule that enhances T-cell mediated antitumor activity (2-fluorofucose). Additional data highlight the growing body of knowledge regarding the ability of auristatin-based ADCs, including ADCETRIS (brentuximab vedotin), to initiate immunogenic cell death, supporting evaluation in combination with checkpoint inhibitors.
SGEN: 40.38 (-0.63)
Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting
BusinessWire - Sun Apr 17, 11:00AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted novel antibody-drug conjugate (ADC) technology advances presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. Data in multiple presentations demonstrate the company's leadership and innovation in the field of ADCs. Presentations will showcase a new auristatin-based drug-linker as well as several novel linkers that expand Seattle Genetics' proprietary ADC technology platform and may enable application of previously inaccessible cytotoxic payloads.
SGEN: 40.38 (-0.63)
Will Perrigo (PRGO) Surprise Earnings Estimates in Q1?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 2:50PM CDT
Perrigo Company (PRGO), which is expected to report first-quarter 2016 results on Apr 19, recorded a negative earnings surprise of 7.22% last quarter.
BIIB: 246.13 (-4.33), PRGO: 98.51 (-1.97), SGEN: 40.38 (-0.63), AMGN: 154.78 (-2.00)
Seattle Genetics Has Returned 22.8% Since SmarTrend Recommendation (SGEN)
Comtex SmarTrend(R) - Fri Apr 15, 1:55PM CDT
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 17th, 2016 at $31.08. In approximately 2 months, Seattle Genetics has returned 22.77% as of today's recent price of $38.15.
SGEN: 40.38 (-0.63)
Seattle Genetics Shares Up 17.4% Since SmarTrend's Buy Recommendation (SGEN)
Comtex SmarTrend(R) - Thu Apr 07, 1:49PM CDT
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 17th, 2016 at $31.08. In approximately 2 months, Seattle Genetics has returned 17.41% as of today's recent price of $36.49.
SGEN: 40.38 (-0.63)
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on April 28, 2016
BusinessWire - Thu Apr 07, 7:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2016 financial results on Thursday, April 28 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 40.38 (-0.63)
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 40.38 (-0.63)
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 40.38 (-0.63)
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 40.38 (-0.63)
Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 40.38 (-0.63)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 38.40 (-0.47), JNJ: 117.01 (+0.01), SGEN: 40.38 (-0.63), SNY: 39.41 (-1.45)
Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 40.38 (-0.63)
What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 40.38 (-0.63), OPHT: 56.33 (+0.17), THLD: 0.47 (-0.02), CHMA: 2.91 (-0.23)
Taking Inventory on Seattle Genetics, Inc. Earnings
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 5:04PM CDT
Seattle Genetics released first-quarter earnings results on Thursday, and while sales of Adcetris continued to grow, they weren't quite as robust as investors were hoping for. Seattle Genetics results: The raw numbers ...
SGEN: 40.38 (-0.63)
Seattle Genetics to Present at Upcoming Investor Conferences
BusinessWire - Wed May 04, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section.
SGEN: 40.38 (-0.63)
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 42.30 (-1.19), SGEN: 40.38 (-0.63), AEGR: 1.37 (-0.13)
Seattle Genetics reports 1Q loss
Automated Insights - Thu Apr 28, 4:59PM CDT
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a loss of $20.5 million in its first quarter.
SGEN: 40.38 (-0.63)
Seattle Genetics Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:02PM CDT
---Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016-
SGEN: 40.38 (-0.63)
5 Biotech Stocks to Bet on This Earnings Season
Zacks Equity Research - Zacks Investment Research - Mon Apr 25, 1:42PM CDT
The happening biotech sector should be a good bet for investors.
BMRN: 81.10 (-1.84), SGEN: 40.38 (-0.63), GILD: 84.45 (-1.32), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25)
Seattle Genetics Highlights Data Supporting Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
BusinessWire - Mon Apr 18, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company's antibody-drug conjugate (ADC) and immuno-oncology programs featured at the upcoming 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. The presentations describe preclinical data with SGN-LIV1A and SEA-CD40, which are in ongoing clinical trials, and highlight two preclinical programs, a novel ADC for the treatment of multiple myeloma (SGN-CD352A) and a small molecule that enhances T-cell mediated antitumor activity (2-fluorofucose). Additional data highlight the growing body of knowledge regarding the ability of auristatin-based ADCs, including ADCETRIS (brentuximab vedotin), to initiate immunogenic cell death, supporting evaluation in combination with checkpoint inhibitors.
SGEN: 40.38 (-0.63)
Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting
BusinessWire - Sun Apr 17, 11:00AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted novel antibody-drug conjugate (ADC) technology advances presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR) being held April 16 through 20, 2016 in New Orleans, LA. Data in multiple presentations demonstrate the company's leadership and innovation in the field of ADCs. Presentations will showcase a new auristatin-based drug-linker as well as several novel linkers that expand Seattle Genetics' proprietary ADC technology platform and may enable application of previously inaccessible cytotoxic payloads.
SGEN: 40.38 (-0.63)
Will Perrigo (PRGO) Surprise Earnings Estimates in Q1?
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 2:50PM CDT
Perrigo Company (PRGO), which is expected to report first-quarter 2016 results on Apr 19, recorded a negative earnings surprise of 7.22% last quarter.
BIIB: 246.13 (-4.33), PRGO: 98.51 (-1.97), SGEN: 40.38 (-0.63), AMGN: 154.78 (-2.00)
Seattle Genetics Has Returned 22.8% Since SmarTrend Recommendation (SGEN)
Comtex SmarTrend(R) - Fri Apr 15, 1:55PM CDT
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 17th, 2016 at $31.08. In approximately 2 months, Seattle Genetics has returned 22.77% as of today's recent price of $38.15.
SGEN: 40.38 (-0.63)
Seattle Genetics Shares Up 17.4% Since SmarTrend's Buy Recommendation (SGEN)
Comtex SmarTrend(R) - Thu Apr 07, 1:49PM CDT
SmarTrend identified an Uptrend for Seattle Genetics (NASDAQ:SGEN) on February 17th, 2016 at $31.08. In approximately 2 months, Seattle Genetics has returned 17.41% as of today's recent price of $36.49.
SGEN: 40.38 (-0.63)
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2016 Financial Results on April 28, 2016
BusinessWire - Thu Apr 07, 7:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2016 financial results on Thursday, April 28 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 40.38 (-0.63)
